ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


SEARCH JOBS

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.

 Key Statistics


Email: info@iderapharma.com
Ownership: Public

Web Site: Idera Pharmaceuticals, Inc.
Employees:
Symbol: IDRA
 









 Company News
Idera Pharmaceuticals, Inc. (IDRA) To Present At The Stifel 2014 Healthcare Conference 11/13/2014 10:39:22 AM
Idera Pharmaceuticals, Inc. (IDRA) And Parent Project Muscular Dystrophy Announce Collaboration To Advance New Treatment Approach For Duchenne Muscular Dystrophy 11/7/2014 10:41:28 AM
Idera Pharmaceuticals, Inc. (IDRA) Reports Third Quarter Financial Results And Announces Expansion Of Rare Disease Development Portfolio 11/7/2014 10:16:34 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Upcoming Presentations Of Data From Oncology Programs At Key Scientific Meetings 11/6/2014 1:09:46 PM
Idera Pharmaceuticals, Inc. (IDRA) To Announce Third Quarter 2014 Financial Results And Corporate Update On November 7, 2014 10/30/2014 8:06:47 AM
Idera Pharmaceuticals, Inc. (IDRA) Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 10/14/2014 8:13:11 AM
Idera Pharmaceuticals, Inc. (IDRA) Reports Second Quarter 2014 Financial Results And Provides Corporate Update 8/12/2014 8:44:39 AM
Idera Pharmaceuticals, Inc. (IDRA) And The Myositis Association Join Forces To Advance The Clinical Development Of A Novel TLR Antagonist, IMO-8400, For The Treatment Of Myositis 8/7/2014 10:37:11 AM
Idera Pharmaceuticals, Inc. (IDRA) And Collaborators Publish Promising Preclinical Data Targeting Microrna With Gene Silencing Oligonucleotide Technology 8/6/2014 10:46:15 AM
Idera Pharmaceuticals, Inc. (IDRA) To Host Conference Call And Webcast To Report Second Quarter 2014 Financial Results 8/5/2014 10:00:37 AM
12345678910...